Changchun Deng, MD, PhD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: Chinese, English
Office Locations
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
2nd Floor
Cleveland, OH 44106
216-844-3954
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
Lobby Level
Cleveland, OH 44106
216-844-3951
Biography: Changchun Deng, MD, PhD
Expertise
Titles
- Medical Director, Lymphoma and CLL, UH Seidman Cancer Center
- Associate Professor, CWRU School of Medicine
Certifications & Memberships
- Hematology - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - New York-Presbyterian/Columbia University Medical Center (2008 - 2010)
Fellowship | Hematology/Oncology
Hematology/Oncology - University Of Texas Southwestern Medical Center (2007 - 2008)
Residency | Internal Medicine
Internal Medicine - Lincoln Medical And Mental Health Center (2004 - 2007)
Research Fellowship | Radiation Oncology
Radiation Oncology - Stanford University (2001 - 2004)
Other Education | Molecular Biology
Molecular Biology - University Of Pittsburgh (1994 - 2001)
Medical Education
Suzhou Medical College (1990)
Featured Videos
Watch to find out more about this University Hospitals provider.
Patient Experience Reviews
Dr. Deng and his team were professional, knowledgeable and respectful.
My experience was very positive. The news was not a happy one for me. All staff were completely pleasant and helpful. I have no complaints. ***
Each time, I waited an hour in exam room after arriving for appointment. After 50 minutes, a staff member informed the doctor would finish up soon
Excellent experienceDr Deng is clearly experienced, passionate about patient care, and empathetic.
Accomplished purpose.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Changchun Deng did not disclose any Outside Relationships with Industry.